COVID-19大流行对急诊科物质使用筛查和过量就诊的影响
本研究基于华盛顿-巴尔的摩地区7家医院电子健康记录,提取2019年11月1日至2020年6月30日急诊就诊数据,比较COVID-19第一波前后SBIRT筛查阳性率及急性酒精/物质中毒或过量临床诊断比例。结果显示筛查阳性率从12.5%升至15.8%(p<0.001),问题饮酒(AUDIT≥7)比例从2.4%升至3.2%(p<0.001),物质中毒/过量占所有筛查者比例从2.1%升至3.1%(p<0.001),阿片类与非阿片类过量比例无变化(67% vs 64%,p=0.33)。提示大流行期间急诊物质使用相关问题增加。
要点
- COVID-19第一波期间SBIRT阳性筛查比例从12.5%升至15.8%(p<0.001),急诊应加强物质使用筛查。
- 问题饮酒(AUDIT评分≥7)比例从2.4%升至3.2%(p<0.001),提示酒精相关问题增加。
- 物质中毒/过量占所有筛查者比例从2.1%升至3.1%(p<0.001),占阳性筛查者比例从16.8%升至20%(p<0.001)。
- 阿片类 vs 非阿片类过量比例无变化(67% vs 64%,p=0.33),提示两类物质均需关注。
- 研究为回顾性描述性分析,仅7家医院,需进一步研究缓解策略。
适用人群与场景
- 研究纳入7家医院急诊就诊患者中临床稳定且愿意完成SBIRT筛查者(共107,930次筛查,大流行前61,961次,大流行后45,969次)。
- 人群以非洲裔美国人(64.7%)和女性(57.1%)为主。
- 排除人群原文未提及。
诊断标准与关键阈值
- 使用经过验证的SBIRT筛查项目对急诊临床稳定且愿意完成筛查的患者进行物质使用筛查。
- 问题饮酒定义为AUDIT评分≥7。
- 急性酒精或物质中毒/过量依据临床诊断。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:回顾性描述性分析,基于7家医院电子健康记录,比较COVID-19第一波前(2019年11月1日–2020年2月29日)与第一波期间(2020年3月1日–6月30日)的急诊数据。
- 主要结果:SBIRT阳性筛查比例从12.5%升至15.8%(p<0.001);问题饮酒(AUDIT≥7)比例从2.4%升至3.2%(p<0.001)。
- 物质中毒/过量占所有筛查者比例从2.1%升至3.1%(p<0.001),占阳性筛查者比例从16.8%升至20%(p<0.001)。
- 酒精中毒占阳性筛查者比例从12.6%升至14.4%(p=0.001)。
- 阿片类 vs 非阿片类过量比例无变化(大流行前67% vs 大流行期间64%,p=0.33)。
- 采用中断时间序列分析评估周趋势变化,但具体结果原文未详细报告。
证据类型、等级与局限
- 证据类型:回顾性观察性研究(基于电子健康记录的描述性分析)。
- 局限:单医疗系统7家医院,回顾性设计,仅描述性统计,未报告置信区间或效应量,部分分析结果未详细展示。
对床旁实践的改变
- 提示COVID-19等公共卫生危机期间急诊应加强物质使用筛查(SBIRT)和过量就诊监测,尤其关注酒精相关问题。
- 阿片类与非阿片类过量比例未变,提示筛查不应仅聚焦阿片类。
- 研究为观察性,不能推断因果关系,适用人群限于临床稳定且愿意筛查的急诊患者。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The COVID-19 pandemic can exacerbate underlying substance use disorder and has impacted this vulnerable population in a variety of ways. There are limited data regarding how this pandemic has impacted emergency department (ED) patient presentations.
METHODS: We extracted data on ED visits from the electronic health record (EHR) of a large healthcare system in the Washington, DC/Baltimore, MD metropolitan area. The dataset includes data from 7 hospitals on ED visits between 11/1/2019-6/30/2020. The health system utilizes a validated screening program for substance use, Screening, Brief Intervention, and Referral to Treatment (SBIRT), for ED patients who are clinically stable and willing to complete screening. We evaluated trends in patients with a positive SBIRT screen and those presenting with a clinical diagnosis of acute alcohol or substance intoxication/overdose before (11/1/19-2/29/2020-pre) and during the first wave of the COVID pandemic (3/1/2020-6/30/2020-post). Data were described using descriptive statistics. Bivariate analyses were conducted using chi-square test and two-sample t-tests. Interrupted time series analysis was used to evaluate the changes in the weekly trends with the start of the pandemic.
RESULTS: There were 107,930 screens performed in the EDs during the study period (61,961 pre, 45,969 post). The population was primarily African American (64.7%) and female (57.1%). Positive SBIRT screens increased from 12.5% to 15.8% during COVID (p < 0.001). Alcohol intoxication presentations increased as a proportion of positive screens from 12.6% to 14.4% (p = 0.001). A higher percentage of screened patients reported problem drinking (AUDIT score ≥ 7) during the pandemic (2.4% pre vs 3.2% post, p < 0.001). Substance intoxication/overdoses among all screened increased from 2.1% to 3.1% (p < 0.001) and as a percentage of positive screens during the pandemic (16.8% to 20%, p < 0.001). The proportion of opioid vs. non-opioid overdoses remained unchanged before (67%) and during the pandemic (64%, p = 0.33).
DISCUSSION: There was an increase in the proportion of positive SBIRT screens and visits for acute overdoses and intoxication during the first wave of the COVID-19 pandemic. Additional research should focus on mitigation strategies to address substance use during this vulnerable time.
参考来源
- Chandran K, Mazer-Amirshahi M, Shankar N, et al. Impact of COVID-19 pandemic on emergency department substance use screens and overdose presentations. Am J Emerg Med. 2021. PMID: 34509745. doi:10.1016/j.ajem.2021.08.058
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。